tetano
Editor, Senior Moderator
er Arkh. 2017;89(10):66-70. doi: 10.17116/terarkh2017891066-70. [h=1][Time course of changes in cytokines (IFN-γ, IFN-α, IL-18, TNF-α) in the treatment of moderate influenza A (H1N1) pdm09 (2013-2016) with oseltamivir (Tamiflu) and umifenovir (Arbidol) alone and in combination with Kagocel].[/h] [Article in Russian; Abstract available in Russian from the publisher]
Popov AF[SUP]1[/SUP], Simakova AI[SUP]1[/SUP], Dmitrenko KA[SUP]1[/SUP], Shchelkanov MY[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] in English, Russian
[h=4]AIM:[/h] To assess correlation of cytokines levels and therapy regimes a relationship of the time course of changes in the cytokines IFN-γ, IFN-α, IL-18, and TNF-α to the treatment option for influenza A (H1N1) pdm09 with umifenovir (Arbidol) 800 mg/day for 5 days (n=50); oseltamivir (Tamiflu) 150 mg/day for 5 days (n=50); umifenovir (Arbidol) 800 mg/day for 5 days in combination with Kagocel 72 mg/day for 2 days.; 36 mg/day for 2 days (n=50); oseltamivir (Tamiflu) (150 mg/day for 5 days) in combination with Kagocel 72 mg/day for 2 days; 36 mg/day for 2 days (n=50). A comparison group consisted of 30 healthy volunteers.
[h=4]MATERIAL AND METHODS:[/h] The state of immunologic reactivity was assessed twice: at admission of the patients to an infectious disease clinic (at 1-3 disease days) and in the early convalescent period (at 7-8 disease days): venous blood samples were collected to determine the concentrations of IFN-γ, IFN-α, IL-18, and TNF-α by a solid-phase enzyme immunoassay.
[h=4]RESULTS:[/h] All the patients in the acute phase of influenza A showed a statistically significant increase in the levels of IFN-γ, IFN-α, and IL-18 as compared with the control group. The groups receiving monotherapy in the early convalescent period had a decrease in the IFN-γ, IFN-α, and IL-18 concentrations that could be compensated by the combined use of the immunomodulator Kagocel. No statistically significant changes in the levels of TNF-α were found in the patients of all the groups, but the groups receiving monotherapy exhibited its lower concentrations in the convalescence period.
[h=4]CONCLUSION:[/h] The combination of etiotropic antiviral drugs with Kagocel enhances the efficiency of antiviral therapy. Monitoring of antiviral cytokines during the treatment of influenza A is a convenient tool to verify the efficiency of antiviral therapy and needs to be more widely introduced into medical practice.
[h=4]KEYWORDS:[/h] Arbidol; Kagocel; Oseltamivir; Tamiflu; Umifenovir; combined therapy; cytokines; influenza; monotherapy
PMID: 29171473 DOI: 10.17116/terarkh2017891066-70
Popov AF[SUP]1[/SUP], Simakova AI[SUP]1[/SUP], Dmitrenko KA[SUP]1[/SUP], Shchelkanov MY[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] in English, Russian
[h=4]AIM:[/h] To assess correlation of cytokines levels and therapy regimes a relationship of the time course of changes in the cytokines IFN-γ, IFN-α, IL-18, and TNF-α to the treatment option for influenza A (H1N1) pdm09 with umifenovir (Arbidol) 800 mg/day for 5 days (n=50); oseltamivir (Tamiflu) 150 mg/day for 5 days (n=50); umifenovir (Arbidol) 800 mg/day for 5 days in combination with Kagocel 72 mg/day for 2 days.; 36 mg/day for 2 days (n=50); oseltamivir (Tamiflu) (150 mg/day for 5 days) in combination with Kagocel 72 mg/day for 2 days; 36 mg/day for 2 days (n=50). A comparison group consisted of 30 healthy volunteers.
[h=4]MATERIAL AND METHODS:[/h] The state of immunologic reactivity was assessed twice: at admission of the patients to an infectious disease clinic (at 1-3 disease days) and in the early convalescent period (at 7-8 disease days): venous blood samples were collected to determine the concentrations of IFN-γ, IFN-α, IL-18, and TNF-α by a solid-phase enzyme immunoassay.
[h=4]RESULTS:[/h] All the patients in the acute phase of influenza A showed a statistically significant increase in the levels of IFN-γ, IFN-α, and IL-18 as compared with the control group. The groups receiving monotherapy in the early convalescent period had a decrease in the IFN-γ, IFN-α, and IL-18 concentrations that could be compensated by the combined use of the immunomodulator Kagocel. No statistically significant changes in the levels of TNF-α were found in the patients of all the groups, but the groups receiving monotherapy exhibited its lower concentrations in the convalescence period.
[h=4]CONCLUSION:[/h] The combination of etiotropic antiviral drugs with Kagocel enhances the efficiency of antiviral therapy. Monitoring of antiviral cytokines during the treatment of influenza A is a convenient tool to verify the efficiency of antiviral therapy and needs to be more widely introduced into medical practice.
[h=4]KEYWORDS:[/h] Arbidol; Kagocel; Oseltamivir; Tamiflu; Umifenovir; combined therapy; cytokines; influenza; monotherapy
PMID: 29171473 DOI: 10.17116/terarkh2017891066-70